Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정연 | * |
dc.contributor.author | 강지은 | * |
dc.date.accessioned | 2021-06-07T16:30:54Z | - |
dc.date.available | 2021-06-07T16:30:54Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 1424-8247 | * |
dc.identifier.other | OAK-29459 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/257536 | - |
dc.description.abstract | Antibiotic-induced dysbiosis may affect the efficacy of immune checkpoint inhibitors. We investigated the impact of antibiotics on the clinical outcomes of nivolumab in patients with non-small cell lung cancer (NSCLC). Patients who received nivolumab for NSCLC between July 2015 and June 2018 and who were followed up until June 2020 were included in a retrospective cohort analysis. Of 140 eligible patients, 70 were on antibiotics. Overall survival (OS) was shorter in patients on antibiotics (ABX) compared to those not on antibiotics (NoABX) (p = 0.014). OS was negatively associated with piperacillin/tazobactam (PTZ) (HR = 3.31, 95% CI: 1.77–6.18), days of therapy (DOT) ≥ 2 weeks (HR = 2.56, 95% CI: 1.30–5.22) and DOT of PTZ. The defined daily dose (DDD) in PTZ (r = 0.27) and glycopeptides (r = 0.21) showed weak correlations with mortality. There was no difference in progression-free survival (PFS) between ABX and NoABX; however, PFS was negatively associated with the antibiotic class PTZ and DOT of PTZ. Therefore, the use of a broad-spectrum antibiotic, such as PTZ, the long-term use of antibiotics more than 2 weeks in total and the large amount of defined daily dose of specific antibiotics were associated with decreased survival in patients receiving nivolumab for NSCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | * |
dc.language | English | * |
dc.publisher | MDPI AG | * |
dc.subject | Antibiotic-induced dysbiosis | * |
dc.subject | Days of therapy | * |
dc.subject | Defined daily dose | * |
dc.subject | Nivolumab | * |
dc.subject | Non-small cell lung cancer | * |
dc.subject | Overall survival | * |
dc.title | Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 14 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Pharmaceuticals | * |
dc.identifier.doi | 10.3390/ph14050445 | * |
dc.identifier.wosid | WOS:000654443200001 | * |
dc.identifier.scopusid | 2-s2.0-85106523359 | * |
dc.author.google | Geum M.J. | * |
dc.author.google | Kim C. | * |
dc.author.google | Kang J.E. | * |
dc.author.google | Choi J.H. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Son E.S. | * |
dc.author.google | Lim S.M. | * |
dc.author.google | Rhie S.J. | * |
dc.contributor.scopusid | 이정연(57191753089) | * |
dc.contributor.scopusid | 강지은(57155481300) | * |
dc.date.modifydate | 20240220111424 | * |